Influence of apolipoprotein A-V on the metabolic fate of triacylglycerol

Current Opinion in Lipidology

Volumn 24, Issue 2, 2013, Pages 153-159

  Sharma, Vineeta ^a   Forte, Trudy ^a   Ryan, Robert ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

apolipoprotein A5; lipid droplet; triacylglycerol; very low density lipoprotein

Indexed keywords

APOLIPOPROTEIN A5; FAT DROPLET; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED HIGH DENSITY LIPOPROTEIN BINDING PROTEIN 1; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIPID STORAGE; LIPOPROTEIN METABOLISM; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEINS; CELL LINE, TUMOR; CYTOSOL; ENDOPLASMIC RETICULUM; HUMANS; INTRACELLULAR MEMBRANES; LIVER; MICE; POLYMORPHISM, GENETIC; PROTEIN INTERACTION MAPPING; RECEPTORS, LIPOPROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP; TRIGLYCERIDES;

MUS; MUS MUSCULUS;

EID: 84875222908     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32835c8c1a     Document Type: Review

References (49)

1. Pennacchio LA, Olivier M, Hubacek JA, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001; 294: 169-173.
2. Sharma V, Ryan RO, Forte TM. Apolipoprotein A-V dependent modulation of plasma triacylglycerol: a puzzlement. Biochim Biophys Acta 2012; 1821: 795-799.
3. Pennacchio LA, Olivier M, Hubacek JA, et al. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 2002; 11: 3031-3038.
4. Hubacek JA, Bohuslavova R, Skodova Z, et al. Polymorphisms in the APOA1/C3/A4/A5 gene cluster and cholesterol responsiveness to dietary change. Clin Chem Lab Med 2007; 45: 316-320.
5. Chandak GR, Ward KJ, Yajnik CS, et al. Triglyceride associated polymorphisms of the APOA5 gene have very different allele frequencies in Pune, India compared to Europeans. BMC Med Genet 2006; 10: 7-76.
6. Lai CQ, Demissie S, Cupples LA, et al. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J Lipid Res 2004; 11: 2096-2105.
7. Soufi M, Sattler AM, Kurt B, Schaefer JR. Mutation screening of the APOA5 gene in subjects with coronary artery disease. J Investig Med 2012; 7: 1015-1019.
8. Kao JT, Wen HC, Chien KL, et al. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet 2003; 12: 2533-2539.
9. Pullinger CR, Aouizerat BE, Movsesyan I, et al. An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients. J Lipid Res 2008; 49: 1846-1854.
10. Huang YJ, Lin YL, Chiang CI, et al. Functional importance of apolipoprotein gene cluster on human chromosome 11. Clin Chim Acta 2012; 1-2: 246-250.
11. Olivier M, Wang X, Cole R, et al. Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics 2004; 83: 912-923.
12. Shu X, Nelbach L, Weinstein MW, et al. Intravenous injection of apolipoprotein A-V reconstituted High-density lipoprotein decreases hypertriglyceridemia in apoav-/-mice and requires glycosylphosphatidylinositol- anchored high-density lipoprotein binding protein. Arterioscler Thromb Vasc Biol 2010; 30: 2504-2509.
13. Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol 2011; 31: 1716-1725. The authors present a balanced review of basic and clinical research addressing the role of triacylglycerol in cardiovascular disease. Questions exist whether triacylglycerol themselves, or the lipoproteins they are associated with, are directly atherogenic.
14. Mansouri RM, Bauge E, Gervois P, et al. Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia. Circ Res 2008; 103: 450-453.
15. Lookene A, Beckstead JA, Nilsson S, et al. Apolipoprotein A-V heparin interactions. Implications for plasma lipoprotein metabolism. J Biol Chem 2005; 280: 25383-25387.
16. Grosskopf I, Shaish A, Afek A, et al. Apolipoprotein A-V modulates multiple atherogenic mechanisms in a mouse model of disturbed clearance of triglyceride-rich lipoproteins. Atherosclerosis 2012; 224: 75-83. Using genetically engineered mouse models, the authors show that apoA-V modulates atherosclerotic lesion development by affecting lipoprotein production and clearance as well as cytokine levels. These findings identify apoA-V as a potential therapeutic target for treatment of atherosclerosis.
17. Forte TM, Shu X, Ryan RO. The ins (Cell) and outs (Plasma) of plasma apolipoprotein A-V. J Lipid Res 2009; 50: S150-S155.
18. Weinberg RB, Cook VR, Beckstead JA, et al. Structure and interfacial properties of human aolipoprotein A-V. J Biol Chem 2003; 278: 34438-34444.
19. Beckstead JA, Wong K, Gupta V, et al. The C terminus of apolipoprotein A-V modulates lipid-binding activity. J Biol Chem 2007; 282: 15484-15489.
20. Wong K, Lee D, Beckstead JA, et al. The N-terminus of apolipoprotein A-V adopts a helix bundle molecular architecture. Biochemistry 2008; 47: 8768-8774.
21. Marcais C, Verges B, Charriere S, et al. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest 2005; 115: 2862-2869.
22. Wong-Mauldin K, Raussens V, Forte TM, Ryan RO. Apolipoprotein A-V N-terminal domain altered lipid interaction properties in vitro explain hypertriglyceridemic phenotype associated with natural truncation mutants. J Biol Chem 2009; 284: 33369-33376.
23. Mauldin K, Lee BL, Oleszczuk M, et al. The carboxyl terminal segment of apolipoprotein A-V undergoes a lipid-induced conformational change. Biochemistry 2010; 49: 4821-4826.
24. van der Vliet HN, Sammels MG, Leegwater AC, et al. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem 2001; 276: 44512-44520.
25. Tijburg LBM, Nyathi CB, Meijer GW, et al. Biosynthesis and secretion of triacylglycerol in rat liver after partial hepatectomy. Biochem J 1991; 277: 723-728.
26. Shu X, Chan J, Ryan RO, Forte TM. ApoA-V association with intracellular lipid droplets. J Lipid Res 2007; 48: 1445-1450.
27. Shu X, Ryan RO, Forte TM. Intracellular lipid droplet targeting by apolipoprotein A-V requires the carboxyl-terminal segment. J Lipid Res 2008; 49: 1670-1676.
28. Walther TC, Farese RV Jr. Lipid droplets and cellular lipid metabolism. Annu Rev Biochem 2012; 81: 687-714.
29. Shu X, Nelbach L, Ryan RO, Forte TM. Apolipoprotein A-V associates with intrahepatic lipid droplets and influences triglyceride accumulation. Biochim Biophys Acta 2010; 1801: 605-608.
30. Ress C, Moschen AR, Sausgruber N, et al. The role of apolipoprotein A5 in nonalcoholic fatty liver disease. Gut 2011; 60: 985-991.
31. Blade AM, Fabritius MA, Hou L, et al. Biogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretion. J Lipid Res 2011; 52: 237-244. In stably transfected, doxycycline-inducible, McA-RH7777 cells, apoA-V expression wasshownto inhibit triacylglycerol secretion by-50%. While this was accompanied by a reduction in VLDL particle diameter, there was no effect on apoB secretion.
32. Gao X, Forte TM, Ryan RO. Influence of apolipoprotein A-V on hepatocyte lipid droplet formation. Biochem Biophys Res Commun 2012; 427: 361-365. Stable transfection of McA-RH7777 with human apoA-V led to increased numbers and size of cytosolic lipid droplets. A molecular model describing the role of apoA-V in intrahepatic triacylglycerol trafficking is presented.
33. Ioka RX, Kang MJ, Kamiyama S, et al. Expressing cloning and characterization of a novel glycosylphosphatidylinositol-anchored high density lipoprotein binding protein, GPIHBP1. J Biol Chem 2003; 278: 7344-7349.
34. Beigneux AP, Davies B, Gin P, et al. Glycosylphosphatidyl-inositol- anchored high density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 2007; 5: 279-291.
35. Gin P, Yin L, Davies BS, et al. The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons. J Biol Chem 2008; 283: 29554-29562.
36. Beigneux AP, Davies BS, Tat S, et al. Assessing the role of the glycosylphospatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) three-finger domain in binding lipoprotein lipase. J Biol Chem 2011; 286: 19735-19743.
37. Beigneux AP, Franssen R, Bensadoun A, et al. Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler Thromb Vasc Biol 2009; 29: 956-962.
38. Franssen R, Young SG, Peelman F, et al. Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects. Circ Cardiovasc Genet 2010; 3: 169-178.
39. Olivecrona G, Ehrenborg E, Semb H, et al. Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia. J Lipid Res 2010; 51: 1535-1545.
40. Rios JJ, Shastry S, Jasso J, et al. Deletion of GPIHBP1 causing severe chylomicronemia. J Inherit Metab Dis 2012; 35: 531-540.
41. Adeyo O, Goulbourne CN, Bensadoun A, et al. GPIHBP1 and the intravascular processing of triglyceride-rich lipoproteins. J Intern Med 2012. doi: 10.1111/joim.12003. [Epub ahead of print] The author's describe recent progress in understanding the role of GPIHBP1 in health and disease and discuss unresolved issues with respect to triglyceride-rich lipoprotein processing.
42. Beigneux AP, Davies BS, Bensadoun A, et al. GPIHBP1, a GPI anchored protein required for the lipolytic processing of triglyceride-rich lipoproteins. J Lipid Res 2009; 50: S57-S62.
43. Gin P, Beigneux AP, Voss C, et al. Binding Preferences for Glycosylphosphatidylinositol HBP1, a Glycosylphosphatidylinositol-Anchored Protein of Capillary Endothelial Cells. Arterioscler Thromb Vasc Biol 2011; 31: 176-182. This study shows that apoA-V binding to GPIHBP1 requires its amino-terminal acidic domain and is independent of its cysteine-rich, Ly6 domain.GPIHBP1 binds LPL but does not bind other lipase family members, apoA-I or HDL.
44. Young SG, Davies BS, Fong LG, et al. GPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons. Curr Opin Lipidol 2007; 18: 389-396.
45. O'Brien PJ, Alborn WE, Sloan JH, et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 2005; 51: 351-359.
46. Nelbach L, Shu X, Konrad RJ, et al. Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice. Lipid Res 2008; 49: 572-580.
47. Henneman P, Schaap FG, Havekes LM, et al. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis 2007; 193: 129-134.
48. Talmud PJ, Cooper JA, Hattori H, et al. The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II. Diabetologia 2006; 49: 2337-2340.
49. Vaessen SF, Schaap FG, Kuivenhoven JA, et al. Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. J Lipid Res 2006; 47: 2064-2070.